The latest imaging tools and technology can revolutionize cancer drug development at every stage. Optimized imaging agents, improved imaging capabilities, better assessment of imaging analysis … these advances are on the cusp of making huge improvements to cancer drug pipelines. 

But it’s not that simple. For tumor imaging’s true potential to be realized, there are several priority areas that need to be ironed out so you can truly use imaging to achieve the best possible clinical and commercial outcome.

Tumor Imaging in Cancer Drug Development is the only meeting in the USA that will allow you to address the key challenges that you face in tumor imaging. 

The conference is designed so you can hear from drug developers and imaging experts specially chosen from Sanofi, Eisai, Genentech, Abbvie, Daiichi Sankyo, Pfizer, Millennium Pharmaceuticals and other leading cancer-focussed organizations. Learn from them. Ask them questions. Discuss your priorities.With the dedicated networking opportunities built into the agenda, you’ll be sure to add these experts to your contact list for future communication and thought-collaboration. 

Attend and access new information, cutting edge ideas, inspiring and perception-changing case studies.  You’ll leave with a dozen new ideas you can implementto improve your imaging capabilities and make a bottom line difference to your organization’s ability to deliver quality results from tumor imaging.